Despite significant advancements, several challenges remain:
Tumor Heterogeneity: The genetic diversity within tumors can make it difficult for a single immunotherapy to be effective. Immune-related Adverse Events (irAEs): Overactivation of the immune system can lead to autoimmune conditions. Resistance Mechanisms: Tumors can develop resistance to immunotherapy over time.
